Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

Xuan LU; Han YAN; Linghui XIA

doi:10.16016/j.1000-5404.202005126

您当前的位置：

首页 >

文章列表页 >

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

更新时间：2026-01-09

- Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation
- Journal of Third Military Medical University Vol. 42, Issue 17, Pages: 1706-1711(2020)
- 作者机构：
- 作者简介：
- 基金信息：
  
  the National Natural Science Foundation for Young Scholars of China(81500109)
- DOI：10.16016/j.1000-5404.202005126
  CLC：
- Received：17 May 2020，
  
  Published：15 September 2020
- 稿件说明：
移动端阅览
Xuan LU, Han YAN, Linghui XIA. Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation[J]. Journal of Third Military Medical University, 2020, 42(17): 1706-1711.
DOI：

Xuan LU, Han YAN, Linghui XIA. Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation[J]. Journal of Third Military Medical University, 2020, 42(17): 1706-1711. DOI： 10.16016/j.1000-5404.202005126.

摘要

Abstract

Objective

and;To evaluate the clinical value of valganciclovir in preemptive treatment of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing the efficacy of the drug with other conventional antiviral drugs (ganciclovir or foscarnet sodium).

Methods

and;Clinical data of 139 patients who received allo-HSCT in our institute from December 2017 to April 2019 were collected and retrospectively analyzed. According to conditioning regimen and graft versus host disease (GVHD) prophylactic regimen on dosage of antithymocyte globulin (ATG)

the patients were divided to ATG-free group (

=28)

and low- (≤6 mg/kg

=73) and high-dose ATG groups (

6 mg/kg

=38). Real-time quantitative polymerase chain reaction (RQ-PCR) was performed to detect the peripheral blood level of CMV-DNA after transplantation. For the patients having CMV viremia (CMV-DNA

400 copies/mL)

valganciclovir and ganciclovir or foscarnet sodium were employed for preemptive treatment. The incidence of CMV viremia

and clearance rate and median time of plasma CMV-DNA were compared among the different dose ATG group and conventional drug group.

Results

and;CMV viremia was observed in 52 patients

with

an incidence of 37.4% (52/139). Within 100 d after transplantation

the incidence of CMV viremia was 14.3%

34.2% and 50.0%

respectively

in the ATG-free group

low- and high-dose ATG groups (

=0.011). Among these 52 patients

the clearance rate of plasmic CMV-DNA was 100% in both valganciclovir group (

=20) and conventional antiviral group (

=32). However

the median time of CMV-DNA clearance was significantly shorter in the valganciclovir group than the conventional antiviral group (21

31 d

=0.022). In the high-dose ATG group

the median time of clearance of plasma CMV-DNA was significantly shorter in the valganciclovir group (6 cases) than the conventional antiviral group (13 cases)(7

35 d

andlt;0.001).

Conclusion

and;Preemptive treatment with valganciclovir can effectively shorten the time and accelerate the clearance of plasma CMV-DNA in patients after allo-HSCT

especially in those patients receiving high-dose ATG before transplantation.

关键词

Keywords

references

ZHANG R SHI W WANG H F Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia Bone Marrow Transplant 2017 52 9 1253 1260 10.1038/bmt.2017.100 ZHANG R, SHI W, WANG H F, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia[J]. Bone Marrow Transplant, 2017, 52(9): 1253-1260. DOI:10.1038/bmt.2017.100.

HENIG I ZUCKERMAN T Hematopoietic stem cell transplantation-50 years of evolution and future perspectives Rambam Maimonides Med J 2014 5 4 10.5041/RMMJ.10162 HENIG I, ZUCKERMAN T. Hematopoietic stem cell transplantation-50 years of evolution and future perspectives[J]. Rambam Maimonides Med J, 2014, 5(4):e0028. DOI: 10.5041/RMMJ.10162.

CHO S LEE D KIM H Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy Int J Mol Sci 2019 20 11 2666 10.3390/ijms20112666 CHO S, LEE D, KIM H. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy[J]. Int J Mol Sci, 2019, 20(11): 2666. DOI:10.3390/ijms20112666.

RUSTIA E VIOLAGO L JIN Z Z Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 2016 22 9 1646 1653 10.1016/j.bbmt.2016.05.014 RUSTIA E, VIOLAGO L, JIN Z Z, et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(9): 1646-1653. DOI:10.1016/j.bbmt.2016.05.014.

曹伟杰万鼎铭李丽异基因造血干细胞移植后巨细胞病毒感染和抢先治疗临床研究中国实验血液学杂志 2016 24 4 1143 1148 10.7534/j.issn.1009-2137.2016.04.034. 曹伟杰, 万鼎铭, 李丽, 等. 异基因造血干细胞移植后巨细胞病毒感染和抢先治疗临床研究[J]. 中国实验血液学杂志, 2016, 24(4): 1143-1148. DOI:10.7534/j.issn.1009-2137.2016.04.034.

CAO W J WAN D M LI L Clinical study of cytomegalovirus infection and preemptive therapy after allogenic hematopoietic stem cell transplantation J Exp Hematol 2016 24 4 1143 1148 10.7534/j.issn.1009-2137.2016.04.034. CAO W J, WAN D M, LI L, et al . Clinical study of cytomegalovirus infection and preemptive therapy after allogenic hematopoietic stem cell transplantation[J ] . J Exp Hematol, 2016, 24(4): 1143-1148. DOI:10.7534/j.issn.1009-2137.2016.04.034.

李乐王昱闫晨华异基因造血干细胞移植后低载量巨细胞病毒血症抢先治疗时机的临床研究中华内科杂志 2018 57 3 191 195 10.3760/cma.j.issn.0578-1426.2015.02.004. 李乐, 王昱, 闫晨华, 等. 异基因造血干细胞移植后低载量巨细胞病毒血症抢先治疗时机的临床研究[J]. 中华内科杂志, 2018, 57(3): 191-195. DOI:10.3760/cma.j.issn.0578-1426.2018.03.008.

LI L WANG Y YAN C H Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients Chin J Intern Med 2018 57 3 191 195 10.1007/s00018-015-1986-z LI L, WANG Y, YAN C H, et al . Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients[J ] . Chin J Intern Med, 2018, 57(3): 191-195. DOI:10.3760/cma.j.issn.0578-1426.2018.03.008.

徐郑丽黄晓军孙于谦巨细胞病毒特异性细胞毒性T淋巴细胞治疗造血干细胞移植后难治复发性巨细胞病毒感染的临床分析中华内科杂志 2015 54 2 101 105 10.3760/cma.j.issn.0578-1426.2015.02.004. 徐郑丽, 黄晓军, 孙于谦, 等. 巨细胞病毒特异性细胞毒性T淋巴细胞治疗造血干细胞移植后难治复发性巨细胞病毒感染的临床分析[J]. 中华内科杂志, 2015, 54(2): 101-105. DOI:10.3760/cma.j.issn.0578-1426.2015.02.004.

XU Z L HUANG X J SUN Y Q Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation Chin J Intern Med 2015 54 2 101 105 10.3760/cma.j.issn.0578-1426.2015.02.004. XU Z L, HUANG X J, SUN Y Q, et al . Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation[J ] . Chin J Intern Med, 2015, 54(2): 101-105. DOI:10.3760/cma.j.issn.0578-1426.2015.02.004.

CIÁURRIZ M ZABALZA A BELOKI L The immune response to Cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients Cell Mol Life Sci 2015 72 21 4049 4062 10.1007/s00018-015-1986-z. CIÁURRIZ M, ZABALZA A, BELOKI L, et al . The immune response to Cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients[J ] . Cell Mol Life Sci, 2015, 72(21): 4049-4062. DOI:10.1007/s00018-015-1986-z.

VERDUYN LUNEL F M RAYMAKERS R VAN DIJK A Cytomegalovirus status and the outcome of T cell-replete reduced-intensity allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2016 22 10 1883 1887 10.1016/j.bbmt.2016.07.009. VERDUYN LUNEL F M, RAYMAKERS R, VAN DIJK A, et al . Cytomegalovirus status and the outcome of T cell-replete reduced-intensity allogeneic hematopoietic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2016, 22(10): 1883-1887. DOI:10.1016/j.bbmt.2016.07.009.

NISHIHORI T SHAHEEN M EL-ASMAR J Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation Immunotherapy 2015 7 10 1059 1071 10.2217/imt.15.70. NISHIHORI T, SHAHEEN M, EL-ASMAR J, et al . Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation[J ] . Immunotherapy, 2015, 7(10): 1059-1071. DOI:10.2217/imt.15.70.

SOUSA H BOUTOLLEAU D RIBEIRO J Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review Biol Blood Marrow Transplant 2014 20 12 1958 1967 10.1016/j.bbmt.2014.08.010. SOUSA H, BOUTOLLEAU D, RIBEIRO J, et al . Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review[J ] . Biol Blood Marrow Transplant, 2014, 20(12): 1958-1967. DOI:10.1016/j.bbmt.2014.08.010..

RAZONABLE R R Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation Curr Opin Infect Dis 2018 31 4 286 291 10.1097/QCO.0000000000000459. RAZONABLE R R. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation[J]. Curr Opin Infect Dis, 2018, 31(4): 286-291. DOI:10.1097/QCO.0000000000000459.

AVERY R K ARAV-BOGER R MARR K A Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection Transplantation 2016 100 10 10.1097/TP.0000000000001418. AVERY R K, ARAV-BOGER R, MARR K A, et al . Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection[J ] . Transplantation, 2016, 100(10): e74-e80. DOI:10.1097/TP.0000000000001418.

MARCHESI F PIMPINELLI F ENSOLI F Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant Hematol Oncol 2018 36 2 381 391 10.1002/hon.2453. MARCHESI F, PIMPINELLI F, ENSOLI F, et al . Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant[J ] . Hematol Oncol, 2018, 36(2): 381-391. DOI:10.1002/hon.2453.

AZEVEDO L S PIERROTTI L C ABDALA E Cytomegalovirus infection in transplant recipients Clinics 2015 70 7 515 523 10.6061/clinics/2015(07)09. AZEVEDO L S, PIERROTTI L C, ABDALA E, et al . Cytomegalovirus infection in transplant recipients[J ] . Clinics, 2015, 70(7): 515-523. DOI:10.6061/clinics/2015(07)09.

TAKAHATA M HASHINO S NISHIO M Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration Transpl Infect Dis 2015 17 6 810 815 10.1111/tid.12456. TAKAHATA M, HASHINO S, NISHIO M, et al . Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration[J ] . Transpl Infect Dis, 2015, 17(6): 810-815. DOI:10.1111/tid.12456.

BOECKH M GARRETT NICHOLS W CHEMALY R F Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation Ann Intern Med 2015 162 1 1 10 10.7326/M13-2729. BOECKH M, GARRETT NICHOLS W, CHEMALY R F, et al . Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation[J ] . Ann Intern Med, 2015, 162(1): 1-10. DOI:10.7326/M13-2729.

WILHELM K CHEMALY R SALIBA R J Oncol Pharm Pract, 2014, 20(4):257-262 The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation 2014 20 4 257 262 10.1177/1078155213501360. WILHELM K, CHEMALY R, SALIBA R, et al ．The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation[J ] . J Oncol Pharm Pract, 2014, 20(4):257-262.

BARKAM C KAMAL H DAMMANN E Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation Bone Marrow Res 2012 2012 874601 10.1155/2012/874601. BARKAM C, KAMAL H, DAMMANN E, et al . Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation[J ] . Bone Marrow Res, 2012, 2012: 874601. DOI:10.1155/2012/874601.

WALKER I PANZARELLA T COUBAN S Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial Lancet Oncol 2016 17 2 164 173 10.1016/S1470-2045(15)00462-3. WALKER I, PANZARELLA T, COUBAN S, et al . Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial[J ] . Lancet Oncol, 2016, 17(2):164-173. DOI:10.1016/S1470-2045(15)00462-3.

WU J MA H LU C Y Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients J Microbiol Immunol Infect 2017 50 3 307 313 10.1016/j.jmii.2015.07.011 WU J, MA H, LU C Y, et al . Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients[J ] . J Microbiol Immunol Infect, 2017, 50(3): 307-313. DOI:10.1016/j.jmii.2015.07.011.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease

Related Author

Xi ZHANG

Ruihao HUANG

Cong ZENG

Xu CHEN

Juan HUA

Tingting CHENG

Xia MA

Yajing XU

Related Institution

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Hematology, Xiangya Hospital, Central South University

Department of Clinical Laboratory, the Second Affiliated Hospital of Zunyi Medical University

Department of Hematology, the Second Affiliated Hospital of Chongqing Medical University

Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)

⁰